Applications

1434 – Anti-Müllerian hormone testing

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Not supported

Application details

Reason for application

New MBS item.

Service or technology in this application

Anti-Müllerian hormone test for the assessment of ovarian function, including ovarian reserve and ovarian responsiveness before or after gonadotoxic treatment

Indication for test

  1. Patients who are being assessed for fertility preservation, prior to gonadotoxic treatment
  2. Long-term follow-up of ovarian function, following completion of gonadotoxic treatment, for the intention of determining complications of gonadotoxic treatment and assess the need for fertility preservation following gonadotoxic treatment, or to recommend the start of assisted reproductive treatment.

Type: Investigative

Medical condition this application addresses

  1. Patients diagnosed with malignancy:
    Currently, 5,660 female Australians aged between 0-45 years are diagnosed with cancer each year.
  2. Patients diagnosed with non-malignant conditions receiving gonadotoxic treatment:

Gonadotoxic treatment can be detrimental to the reproductive potential for several non-malignant medical conditions. Examples of these conditions include:

  • gastrointestinal diseases
  • rheumatologic
  • inflammatory bowel diseases (IBDs),
  • rheumatologic disorders
  • non-malignant hematologic conditions
  • autoimmune/vasculitis/glomerular disorders
  • gynaecologic conditions
  • metabolic diseases.

Meetings to consider this application

  • PASC meeting:
    • 14 April 2016
    • 11 - 12 August 2016
  • ESC meeting: 8 - 9 February 2018
  • MSAC meeting: 28 - 29 March 2018